Ergoteles LLC Incyte Corp Transaction History

Ergoteles LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $551,411 - $693,055	8,332 New	8,332 $633,000
Q1 2022 May 13, 2022	SELL	$66.02 - $79.71 $14.1 Million - $17 Million	-213,164 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $13.5 Million - $15.8 Million	213,164 New	213,164 $15.6 Million
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $851,095 - $1.04 Million	-12,394 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$79.87 - $87.53 $989,908 - $1.08 Million	12,394 New	12,394 $1.04 Million
Q1 2021 May 12, 2021	SELL	$76.02 - $100.5 $480,674 - $635,461	-6,323 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$80.74 - $97.7 $510,519 - $617,757	6,323 New	6,323 $550,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.